Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Drug-resistant Focal Seizure Clear all
Completed Not applicable Interventional

Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy

NCT04770337
View directory record Official record
Conditions
Refractory Epilepsy, Focal Seizure, Seizures, Focal, Seizures, Epilepsy in Children, Epilepsy, Epilepsy, Tonic-Clonic
Interventions
STARSTIM device, Sham Device
Device
Lead sponsor
Neuroelectrics Corporation
Industry
Eligibility
9 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
18
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 23, 2026, 8:21 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

NCT03739840
View directory record Official record
Conditions
Drug-Resistant Epilepsy, Focal-Onset Seizures
Interventions
Padsevonil, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
32
States / cities
Chandler, Arizona • Tucson, Arizona • Carlsbad, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Jul 23, 2026, 8:21 PM EDT
Terminated Phase 2 Interventional Results available

An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

NCT04686786
View directory record Official record
Conditions
Seizures
Interventions
CVL-865
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
26
States / cities
Little Rock, Arkansas • New Haven, Connecticut • Gulf Breeze, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Jul 23, 2026, 8:21 PM EDT
Terminated Phase 4 Interventional Results available

BOTOX Effects on Seizure Severity and Susceptibility

NCT05605756
View directory record Official record
Conditions
Drug-resistant Focal Seizure
Interventions
OnabotulinumtoxinA 145 UNT [Botox]
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 23, 2026, 8:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Novel Helmet Design in Patients With Seizures

NCT03443388
View directory record Official record
Conditions
Drug Resistant Epilepsy, Drop Seizures, Generalized Tonic Clonic Seizure, Complex Partial Seizure, Fall Due to Seizure
Interventions
Hövding inflatable helmet
Device
Lead sponsor
Michael A. Gelfand, MD, PhD
Other
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Jul 23, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

External Trigeminal Nerve Stimulation for Epilepsy

NCT01159431
View directory record Official record
Conditions
Epilepsy, Seizure Disorders
Interventions
Trigeminal Nerve Stimulation
Device
Lead sponsor
Olive View-UCLA Education & Research Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Los Angeles, California • Sylmar, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2013 · Synced Jul 23, 2026, 8:21 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

NCT06309966
View directory record Official record
Conditions
Focal Epilepsy
Interventions
BHV-7000, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
50
States / cities
Peoria, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 23, 2026, 8:21 PM EDT
Recruiting Not applicable Interventional

Non-Invasive Low Intensity Focused Ultrasound Stimulation for Drug-Resistant Epilepsy

NCT07680842
View directory record Official record
Conditions
Drug-Resistant Epilepsy, Epilepsy, Epilepsy (Treatment Refractory), Epilepsy Comorbidities, Epilepsy, Drug Resistant, Epilepsy, Generalized, Epilepsy, Focal
Interventions
Target optimization using LIFU, Serial LIFU stimulation
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 23, 2026, 8:21 PM EDT
Terminated Phase 4 Interventional Results available

Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy

NCT04650204
View directory record Official record
Conditions
Intractable Epilepsy, Malignant Glioma, Seizure Disorder, WHO Grade 2 Glioma, WHO Grade 3 Glioma
Interventions
Anticonvulsant Agent, Perampanel, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Jul 23, 2026, 8:21 PM EDT
Enrolling by invitation Phase 2 Interventional

Long-term Safety and Tolerability of BHV-7000

NCT06443463
View directory record Official record
Conditions
Focal Epilepsy
Interventions
BHV-7000
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
115
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 23, 2026, 8:21 PM EDT
Recruiting Phase 1 Interventional

Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy

NCT02531880
View directory record Official record
Conditions
Epilepsy
Interventions
Mangafodipir, Gadolinium
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 8:21 PM EDT
Recruiting Phase 2 Interventional

Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

NCT05518578
View directory record Official record
Conditions
Epilepsy, Seizures, Epileptic
Interventions
SPN-817
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Jacksonville, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 23, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

NCT04244175
View directory record Official record
Conditions
Seizures
Interventions
Placebo, CVL-865
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
37
States / cities
Little Rock, Arkansas • Downey, California • Loma Linda, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Jul 23, 2026, 8:21 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension

NCT01963208
View directory record Official record
Conditions
Drug Resistant Partial Onset Seizure
Interventions
ganaxolone, Placebo
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Jul 23, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy

NCT03283371
View directory record Official record
Conditions
Epilepsy, Focal Seizures, Partial Seizures
Interventions
Natalizumab, Placebo
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Jul 23, 2026, 8:21 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy

NCT06388707
View directory record Official record
Conditions
Drug Resistant Epilepsy, Epilepsy, Seizures, Focal, Seizure, Seizure Disorder
Interventions
NaviFUS System
Device
Lead sponsor
NaviFUS Corporation
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Palo Alto, California • Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 23, 2026, 8:21 PM EDT
Terminated Phase 3 Interventional Results available

A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures

NCT02519439
View directory record Official record
Conditions
Drug Resistant Partial Onset Seizure
Interventions
ganaxolone
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Santa Monica, California • Lexington, Kentucky • Golden Valley, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Jul 23, 2026, 8:21 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

NCT06132893
View directory record Official record
Conditions
Focal Epilepsy
Interventions
BHV-7000, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
61
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 23, 2026, 8:21 PM EDT
Terminated Phase 2 Interventional Results available

Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

NCT03370120
View directory record Official record
Conditions
Drug-Resistant Epilepsy, Focal-Onset Seizures
Interventions
Padsevonil
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
25
States / cities
Chandler, Arizona • La Jolla, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2021 · Synced Jul 23, 2026, 8:21 PM EDT
Recruiting Not applicable Interventional

Optimizing Therapy in Epilepsy Using Seizure Forecasts Via EEG and Wearables

NCT07012148
View directory record Official record
Conditions
Focal Epilepsy, Generalized Seizure, Drug Refractory Epilepsy
Interventions
UNEEG SubQ device
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 23, 2026, 8:21 PM EDT
Terminated Not applicable Interventional

RNS System RESPONSE Study

NCT04839601
View directory record Official record
Conditions
Epilepsy, Partial Seizure, Neurostimulator; Complications, Drug Resistant Epilepsy, Focal Epilepsy
Interventions
RNS System
Device
Lead sponsor
NeuroPace
Industry
Eligibility
12 Years to 17 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Grand Rapids, Michigan • Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Jul 23, 2026, 8:21 PM EDT
Recruiting Phase 3 Interventional

Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

NCT05135091
View directory record Official record
Conditions
Mesial Temporal Lobe Epilepsy
Interventions
NRTX-1001, Sham Comparator
Biological · Procedure
Lead sponsor
Neurona Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2043
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 23, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy

NCT03373383
View directory record Official record
Conditions
Drug-resistant Epilepsy, Focal-Onset Seizures
Interventions
Padsevonil, Placebo
Drug · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
27
States / cities
Chandler, Arizona • Little Rock, Arkansas • La Jolla, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Jul 23, 2026, 8:21 PM EDT